Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394211 · ClinicalTrials.gov registry record · Phase 2
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01394211 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 2 participants.
The verdict
NCT01394211, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer. Pazopanib hydrochloride and anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride and anastrozole together before surgery may make the tumor smaller and reduce the amount of normal cells that have to be removed
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG anastrozole
- DRUG pazopanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-07-13 |
| Est. Completion | 2012-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01394211
The ClinicalTrials.gov registry entry for NCT01394211 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which therapeutic conventional surgery is the first listed.
NCT01394211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01394211 about?
NCT01394211 is a clinical study titled "Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer". This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer. Pazopanib hydrochloride and anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed ...
What is the current status of trial NCT01394211?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-07-13. Estimated completion is 2012-04-12.
What interventions are being tested in trial NCT01394211?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), anastrozole (DRUG), pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01394211?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.